CRSP stock: buy or sell
Updated on:
Jul 29th, 2021
1
CRSP stock brief
- CRISPR Therapeutics stock grew 1.98% to close at $119.75 on the stock market on Wednesday, and broke a streak of 4 sessions in red.
- Last Monday, CRISPR Therapeutics presented its Q2 financial report
- The stock is configuring an uptrend pattern since last May, when it bottomed at $95.11. This uptrend marked a 25.91% gain
- CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for serious human diseases.
Should I buy CRISPR Therapeutics stock?
All successful traders recommend adhering to a trading strategy and not make decisions based on subjective opinions, rumors or feelings. Trading strategies are meant for helping you in the decision process of what stocks to pick and when is the best moment to buy them. At Stocks2.com, we like to use very simple but trusted and powerful trend following trading strategies. Simple things usually work the best
Is $CRSP stock a buy?
In the current situation of CRISPR Therapeutics there is just one buy setup eligible:
Uptrend buy setup
CRISPR Therapeutics stock is in an uptrend since last May that so far marked a gorgeous 26.00% gain. Price marked a local bottom in this uptrend at $113.34 on Tuesday, and since then it bounced up a 5.66%. Breaking out over $169.76 - it's last top - will be a good entry point if CRISPR Therapeutics resumes the uptrend. If you decide to enter this trade, the suggested stop loss is at $152.78
| Buy setup | Buy point | Stop loss | Risk |
| Uptrend buy setup | $169.76 | $152.78 | 10.00% |
Should I sell CRISPR Therapeutics stock?
Knowing when to sell a stock is even more difficult than knowing when to buy it. Trading strategies allow us to avoid rash decisions based on our personal sentiments or the noise surrounding the market. Our trading system selects very simple strategies to guide us on when is the best time to sell a stock. Be aware that these strategies should not be used for shorting CRISPR Therapeutics stock
A golden rule is that you must never mantain a trading operation that shows a greater losses than those expected by the time of purchase. When to sell your stock always has to be determined by the stop-loss (automatic or manual)
Is it time to sell CRISPR Therapeutics stock?
In the current situation of CRISPR Therapeutics there is not any eligible sell setup, so CRISPR Therapeutics stock holders with operations in profit can keep their positions
CRISPR Therapeutics ratings
In the previous 30 days we couldn't find any rating for CRISPR Therapeutics
CRISPR Therapeutics stock analysis
Since last May, CRISPR Therapeutics has been drawing an uptrend that by now marked a gorgeous 25.91%. Rising tops and bottoms can be seen easily on a chart and how price action offered very few buy points on the breakouts. Latest low was on Tuesday, when price bounced at $113.34. Like in all uptrends, price needs to rest and now price is consolidating the gains in a range between $169.76 and $113.34
SMAs overview
Supports and resistances
The current resistances are:
The current support levels are:
Bollinger bands
Relative strength index
The RSI dropped below the overbought level of 70 on July 6 after just crossing to the overbough zone for a single day (weak signal). The RSI reading on Wednesday was 38.09. Since that level was lost, CRISPR Therapeutics shares collapsed a 23.18%
CRISPR Therapeutics stock price history
CRISPR Therapeutics went public on Oct 19th, 2016 priced at $15.00 per share1. Since then, CRSP stock surged by 698.33%, with an average of 174.58% per year. If you had invested thousand dollars in CRISPR Therapeutics stock on Oct 2016, it would be valued $7,983.33 today.
1: Adjusted price after possible price splits or reverse-splits
Price target for CRISPR Therapeutics stock
How much a stock will be priced tomorrow or next week is quite unpredictable. Banks and financial organisations issue their analysis forecasting how a particular stock will performance in the future.
The following table shows the price predictions published by analysts in the last 30 days. Again, these targets are not direct recommendations for individual traders and should not be followed blindly.
In the last month we couldn't find any price target posted for CRISPR Therapeutics stock.
Earnings and financials
CRISPR Therapeutics ($CRSP) hosted the quarterly earnings event and presented the report last Monday.
This compares to Earnings of $-1.30 per share same quarter last year, so reported EPS means 100.00%. Revenue exploded a 243.31% on an annualized basis in the , from $1.6M to $5.4M last quarter.CRSP ($CRSP) is hosting the quarterly earnings call next October.
CRISPR Therapeutics performance
| Company | 1m | 3m | 6m |
|---|---|---|---|
| CRISPR Therapeutics ($CRSP) | -20.70% | -12.40% | -29.10% |
Please read:
The comments written in this post are personal and should not be followed as recommendations for you to buy or sell shares. The author of this article does not have any knowledge of the particular circumstances of the reader, his or her finances or his or her own best interests at any given time. All users should speak with their financial advisor before buying or selling any securities Thoughts are posted for learning purposes onlyCRSP summary
| Wednesday, July 28th, 2021 | |
|---|---|
| Open | $117.48 |
| Close | $119.75 |
| Day range | $116.01 - $121.4 |
| Previous close | $117.43 |
| Session gain | 1.98% |
| Average true range | $7.58 |
| 50d mov avg | $128.27 |
| 100d mov avg | $124.25 |
| 200d mov avg | $131.77 |
| Earnings date | October 26th, 2021 |